Innovation & Research
The founding team of Amiro comes from leading scientific research companies such as Mindray Medical, Peninsula Medical, L'Oreal Group, CSOT, and Procter & Gamble. They graduated from world-renowned universities such as Tsinghua University, Zhejiang University, and MIT. The AMIRO team hopes to use a scientific and dermatological perspective to find the most accurate and appropriate care for skin.
Cooperating with Shanghai Jiao Tong University and Zhejiang University to build a joint research and development center for smart photoelectric medical technology in the field of skin treatment. AMIRO team members account for more than 50%.
Awards & Investors
National High-tech Enterprise; Shenzhen High-tech High-Growth Top 20; Deloitte China Top 50; 2021 New Consumer Domestic Brand with the Most Growth Potential.
Amiro early investors include Tencent Investment, Xiaomi Technology, Shunwei Capital, Qingliu Capital, Dachen Financial Intelligence, Honghui Capital, etc. Series C funding will be mainly used for technology research and development, category expansion, medical system establishment and brand upgrade.
Research & Development
AMIRO has applied for more than 370 patents in total. With scientific data and clinical test reports, it provides users with a new generation of methods that improve skincare.
Industry research
AMIRO has completed the clinical trial registration of Class III medical devices with the Guangdong Provincial Food and Drug Administration in accordance with the requirements of the National Quality Management Standard for Clinical Trials of Medical Devices, it has launched Class III medical device registrations in many qualified large tertiary hospitals in China. Clinical trials are currently being carried out, leading the high-quality development of the industry.
AMIRO cooperated with a well-known tertiary hospital in Chengdu to carry out the first domestic clinical study on the "Evaluation of the Impact of Home Radio Frequency Device ARF001 (AMIRO Red Light Triangular Radio Frequency Device) on Skin Physiological Conditions" for people with chloasma. The report was officially released.
The results showed that after continuous use of AMIRO Red Light Triangular Radiofrequency Device for subjects with melasma in the stable stage, facial wrinkles and texture showed a significant improvement trend, and the melanin value of both cheeks was significantly reduced, confirming that AMIRO Red Light Triangular Radiofrequency Device can meet the safe and anti-aging needs of people with chloasma, and it is combined with arbutin to lighten pigments.
